Press Release
JBCHEPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than Nifty Smallcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
JB Pharma reported Q4 FY26 revenue of Rs 904 crores, down 5% YoY from Rs 949 crores, impacted by post-acquisition integration activities including distribution network optimization, discontinuation of low-margin trade generics, and shipment delays. Q4 PAT declined 30% to Rs 101 crores (adjusted PAT at Rs 150 crores). For full year FY26, revenue grew 6% to Rs 4,148 crores while PAT grew 8% to Rs 709 crores. Gross margin improved to 70% in Q4 vs 66% a year ago, and EBITDA margin expanded to 27% from 25%. India business grew 2% in Q4 and 9% for FY26, with chronic portfolio outperforming at 19% growth. International formulations declined 9% in Q4 but grew 2% for FY26. The company attributes Q4 weakness to temporary integration effects and expects recovery from H1 FY27.
Q4 showed a temporary operational reset due to parent company integration, resulting in revenue and profit decline. However, margin improvement and full-year growth demonstrate underlying business strength. Shareholders should expect recovery in H1 FY27 as integration normalizes.